PDS Biotechnology (PDSB) Misses Q1 EPS by 24c
Get Alerts PDSB Hot Sheet
Join SI Premium – FREE
PDS Biotechnology (NASDAQ: PDSB) reported Q1 EPS of ($0.39), $0.24 worse than the analyst estimate of ($0.15).
First Quarter 2020 and Recent Business Highlights
- Initiated novel vaccine development programs for COVID-19 and universal influenza;
- Announced pre-clinical collaboration with Farmacore Biotechnology for tuberculosis;
- Delayed initiation of Phase 2 VERSATILE-002 trial for PDS0101 in recurrent/metastatic head and neck cancer due to the global COVID-19 pandemic;
- Secured the U.S. composition of matter patent for the Versamune® platform;
- Expanded the previously disclosed Cooperative Research and Development Agreement with the National Cancer Institute to include preclinical and clinical development of PDS0103;
- Appointed Kamil Ali-Jackson, Esq. and Dr. Ilian Iliev to the Board of Directors; and
- Successfully completed an underwritten public offering of our common stock in February 2020 with net proceeds of approximately $11.9 million after deducting underwriting discounts and commissions, not including other offering expenses.
“We have continued to leverage the versatility and potency of our Versamune® platform, as we expand our development program to include vaccines to protect against infectious diseases such as COVID-19 and influenza. We believe that Versamune’s® ability to induce a superior range of protective immune responses - including neutralizing antibodies, killer T-cells and memory T-cells - uniquely positions PDS to develop more effective vaccines to provide long-term protection against the spread of agents with pandemic potential. We have recently initiated pre-clinical testing for our COVID-19 vaccine candidates and are in active discussions with both government agencies and NGOs to determine the most expeditious path forward,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech.
“We remain committed to our immuno-oncology programs, including two upcoming Phase 2 studies for PDS0101 with our partners at the National Cancer Institute. We also look forward to initiating our third Phase 2 program evaluating the combination of PDS0101 and Merck’s KEYTRUDA® in HPV16-associated head and neck cancer for first line treatment of recurrent/metastatic disease when conditions to conduct the study improve,” Dr. Bedu-Addo concluded.
For earnings history and earnings-related data on PDS Biotechnology (PDSB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
- MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
- Wipro (WIT) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!